Alzamend Neuro (ALZN) vs Can-Fite Biopharma (CANF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alzamend Neuro is the larger company by market cap ($6.5 million vs $6.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | ALZN | CANF |
|---|---|---|
| Share price | $1.34 | $2.00 |
| Market cap | $6.47M | $6.06M |
| 1-day change | -2.19% | -4.76% |
| YTD return | — | -46.50% |
| 1-year return | — | -82.17% |
| 5-year return | — | -99.31% |
| EPS (TTM) | $-2.30 | $-13.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.68 | $12.40 |
| 52-week low | $0.84 | $1.96 |
| Distance from 52-week high | -50.00% | -83.87% |
| Average volume | 89.15K | 387.60K |
| Shares outstanding | 4.83M | 3.03M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
ALZN vs CANF FAQ
Which is bigger, Alzamend Neuro or Can-Fite Biopharma?
Alzamend Neuro (ALZN) is larger, with a market capitalization of $6.47M compared with $6.06M for Can-Fite Biopharma (CANF).
Are Alzamend Neuro and Can-Fite Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.